Fibroblast Growth Factor 23 (FGF23)

Class Peptide hormoneReceptor FGFR1c

Function

Fibroblast growth factor 23 is a peptide hormone involved in phosphate regulation, vitamin D metabolism, kidney signaling, and mineral homeostasis. FGF23 functions as a major endocrine regulator coordinating communication between bone tissue, kidneys, intestines, and mineral metabolism pathways.

The hormone lowers circulating phosphate levels by reducing renal phosphate reabsorption and suppressing calcitriol synthesis within the kidneys. Through these actions, FGF23 contributes to maintenance of balanced phosphate availability and mineral homeostasis. The hormone also participates in communication between skeletal tissues and renal endocrine systems during adaptation to changing mineral and nutrient conditions.

Production

FGF23 is produced mainly by osteocytes and osteoblasts within bone tissue. Synthesis increases in response to elevated phosphate availability, calcitriol signaling, and mineral-related endocrine communication pathways. Bone therefore functions as an endocrine organ that actively regulates systemic phosphate physiology through FGF23 secretion.

After production, FGF23 circulates systemically and targets kidney tissue where it modulates phosphate transport and vitamin D-related signaling pathways.

Regulation

FGF23 production is regulated by phosphate intake, calcitriol signaling, parathyroid hormone pathways, bone metabolism, and mineral availability. Elevated phosphate and increased calcitriol activity strongly stimulate secretion, while feedback systems involving mineral balance help stabilize circulating concentrations.

FGF23 acts through fibroblast growth factor receptors together with the Klotho co-receptor expressed mainly within renal tissues. Receptor activation influences phosphate transport proteins, vitamin D metabolism enzymes, and mineral-related endocrine signaling pathways. Through these integrated skeletal-renal endocrine systems, FGF23 coordinates phosphate homeostasis, calcitriol regulation, kidney signaling, and systemic mineral balance.

Identity & Secretion

Primary Source GlandOsteocytes (bone)

Secretion PatternIncreases with higher phosphate and calcitriol; elevated in CKD and phosphate-wasting disorders

Half-life50 min

PrecursorPrepro-FGF23 (FGF23 precursor peptide)

Nutrient Requirements

Nutrient Precursors

Amino acids (protein) supply for peptide synthesis

Required Vitamins

Vitamin D sufficiency supports physiologic phosphate–vitamin D feedback; B-vitamins support general protein synthesis

Required Minerals

Phosphorus, calcium, magnesium (systems mineral balance)

Key Foods

Whole grains and legumes (phytate-bound phosphorus with lower bioavailability); high-potassium vegetables and fruits as part of renal-friendly patterns

Targets & Signaling

Target Tissues

Kidney (proximal/distal tubules), parathyroid, bone; systemic vascular–renal axis (context)

Feedback Loops

Phosphate–vitamin D–PTH axis with Klotho co-receptor; negative feedback via phosphate lowering

Second Messengers

MAPK/ERK; PLCγ (context); downstream transcriptional effects via FGFR signaling

Pathways Involved

Renal phosphate handling; vitamin D activation/inactivation; bone–kidney endocrine loop

Key Functions

Reduces renal phosphate reabsorption; suppresses 1α-hydroxylase to lower calcitriol; coordinates phosphate–vitamin D–PTH balance

Plant-Based Focus

Plant-forward patterns emphasizing minimally processed, lower-phosphate-additive foods can support favorable phosphate balance

Clinical Context

Normal Range≤59

Unitspg/mL

Assay Notes
Report assay type (intact vs C-terminal). Interpret alongside serum phosphate and kidney function; adult intact FGF23 upper ref. ≈59 pg/mL.

Linked Knowledge

Phytochemicals

Amino Acids

Foods

Whole grains, legumes, vegetables, fruits (dietary patterns minimizing phosphate additives)

Vitamins

Vitamin D (endocrine partner); B-vitamins (general protein metabolism, context)

Minerals

Phosphorus, calcium, magnesium

Cancers (context)

Tumor-induced osteomalacia (phosphaturic mesenchymal tumors with ectopic FGF23 expression) — context documentation

Ailments

X-linked hypophosphatemia (XLH); autosomal dominant/recessive hypophosphatemic rickets; CKD–mineral and bone disorder; osteomalacia

Dietary Modulators

Limit phosphate additives (processed meats/colas/processed foods). Favor plant sources with lower phosphate bioavailability.

Inhibitors / Activators

Inhibitors

Lower dietary phosphate load; reduced calcitriol synthesis; negative feedback when serum phosphate decreases.

Activators

Increased dietary phosphate intake; elevated calcitriol (1,25D); inflammatory cytokines such as IL-6; iron deficiency states.

Summary

Bone-derived peptide that lowers serum phosphate by reducing renal reabsorption and calcitriol synthesis via FGFR1c–α-Klotho signaling.

SUMMARY OF EFFECTS ON THE BODY

Supports phosphate balance, bone mineralization, and renal–endocrine homeostasis; dysregulation contributes to rickets/osteomalacia and CKD-MBD.

Research

Adult intact FGF23 reference upper limit ≈59 pg/mL; half-life on the order of ~46–58 minutes; signaling requires α-Klotho.